Published in Cancer Microenviron on October 27, 2012
Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 2.29
In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature (2014) 2.05
Regulatory T cells in nonlymphoid tissues. Nat Immunol (2013) 1.69
Natural and induced T regulatory cells in cancer. Front Immunol (2013) 1.15
Regulatory T cells and the immune aging process: a mini-review. Gerontology (2013) 1.10
Ionizing radiation, ion transports, and radioresistance of cancer cells. Front Physiol (2013) 1.09
Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol (2014) 1.00
Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol (2014) 1.00
Adipose tissue-resident regulatory T cells: phenotypic specialization, functions and therapeutic potential. Immunology (2014) 0.95
Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Cell Death Differ (2013) 0.95
How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development. Front Immunol (2013) 0.91
From mice to humans: developments in cancer immunoediting. J Clin Invest (2015) 0.90
Tissue resident regulatory T cells: novel therapeutic targets for human disease. Cell Mol Immunol (2015) 0.87
Dendritic cells, inflammation, and breast cancer. Cancer J (2013) 0.86
A role for T-lymphocytes in human breast cancer and in canine mammary tumors. Biomed Res Int (2014) 0.85
Following up tumor-specific regulatory T cells in cancer patients. Oncoimmunology (2013) 0.80
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. Vaccines (Basel) (2016) 0.78
VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer. Oncoimmunology (2013) 0.78
The Prognostic Value of Forkhead Box P3 Expression in Operable Breast Cancer: A Large-Scale Meta-Analysis. PLoS One (2015) 0.77
Dissecting the regulatory microenvironment of a large animal model of non-Hodgkin lymphoma: evidence of a negative prognostic impact of FOXP3+ T cells in canine B cell lymphoma. PLoS One (2014) 0.76
Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients. Oncoimmunology (2014) 0.75
Large molecular systems landscape uncovers T cell trapping in human skin cancer. Sci Rep (2016) 0.75
Classical Hodgkin Lymphoma with Positive Epstein-Barr Virus Status is Associated with More FOXP3 Regulatory T Cells. Med Sci Monit (2016) 0.75
New Insights into Regulatory T Cells: Exosome- and Non-Coding RNA-Mediated Regulation of Homeostasis and Resident Treg Cells. Front Immunol (2016) 0.75
Towards tumor immunodiagnostics. Ann Transl Med (2016) 0.75
The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nat Commun (2017) 0.75
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 16.28
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
CTLA-4 control over Foxp3+ regulatory T cell function. Science (2008) 12.67
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol (2010) 9.72
Foxp3-dependent programme of regulatory T-cell differentiation. Nature (2007) 9.48
Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol (2007) 7.86
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44
CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol (2007) 6.94
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol (2006) 6.23
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med (1996) 6.11
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol (2008) 6.01
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62
Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med (2001) 5.56
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol (2007) 5.28
Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity (2012) 4.98
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med (2004) 4.35
Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol (2011) 4.29
Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U S A (2009) 4.25
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature (2011) 4.07
Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity (2004) 3.81
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res (2008) 3.57
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A (2008) 3.04
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood (2009) 2.88
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol (2009) 2.83
Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol (2012) 2.71
Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol (2007) 2.69
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood (2005) 2.60
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60
Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res (2006) 2.56
Helios expression is a marker of T cell activation and proliferation. PLoS One (2011) 2.55
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2008) 2.54
High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood (2006) 2.40
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res (2005) 2.38
The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res (2012) 2.37
The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res (2007) 2.30
Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2009) 2.18
Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res (2011) 2.16
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood (2008) 2.09
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res (2009) 2.02
Regulatory T cells in cancer. Adv Cancer Res (2010) 2.02
Anaplastic large cell malignant lymphoma with extensive eosinophilic or neutrophilic infiltration. Histopathology (1998) 2.00
Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res (2006) 1.97
Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood (2008) 1.96
High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer (2010) 1.96
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood (2009) 1.93
Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol (2007) 1.92
Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle (2009) 1.87
Regulatory T-cell compartmentalization and trafficking. Blood (2006) 1.86
Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res (2008) 1.82
The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol (2011) 1.82
CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother (2005) 1.80
IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol (2011) 1.76
Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest (2009) 1.73
CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol (2009) 1.70
Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol (2008) 1.69
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A (2010) 1.67
Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res (2007) 1.66
Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2007) 1.66
Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther (2007) 1.64
Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet (2001) 1.58
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev (2011) 1.55
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood (2011) 1.51
TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One (2012) 1.44
Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol (2005) 1.43
What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol (2012) 1.42
A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother (2010) 1.40
Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34
CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res (2012) 1.34
Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol (2009) 1.34
Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res (2005) 1.27
Comment on "Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells". J Immunol (2010) 1.27
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab Invest (2011) 1.22
Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res (2010) 1.21
Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother (2007) 1.21
Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother (2008) 1.18
Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease. Oral Oncol (2009) 1.18
The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences. Cancer Res (2012) 1.17
Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells. Eur J Immunol (2010) 1.16
The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res (2009) 1.14
Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta Oncol (2007) 1.13
The immune system and cancer. Cancer Biother Radiopharm (2009) 1.11
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology (2012) 1.09
Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer. Am J Pathol (2009) 1.06
FOXP3 and survival in urinary bladder cancer. BJU Int (2011) 1.05
VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur J Immunol (2010) 1.05
Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol (2011) 1.04
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Molecular characterization of mitochondrial apoptosis-inducing factor. Nature (1999) 14.41
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ (2008) 10.45
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2011) 9.44
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science (1994) 8.73
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev (1997) 5.65
Molecular mechanisms of cisplatin resistance. Oncogene (2011) 5.20
Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature (2001) 5.07
Organelle-specific initiation of cell death pathways. Nat Cell Biol (2001) 5.03
Mitochondrial control of nuclear apoptosis. J Exp Med (1996) 5.01
Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol (2000) 4.89
Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med (1995) 4.88
Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science (1998) 4.84
DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol (1998) 4.61
Lysosomal membrane permeabilization in cell death. Oncogene (2008) 4.40
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27
Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med (1995) 4.20
Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci (2000) 4.14
Regulation of autophagy by the inositol trisphosphate receptor. Cell Death Differ (2007) 4.12
Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med (1996) 4.00
Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2009) 3.90
The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol (2001) 3.66
Chloromethyl-X-Rosamine is an aldehyde-fixable potential-sensitive fluorochrome for the detection of early apoptosis. Cytometry (1996) 3.45
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
Cell death modalities: classification and pathophysiological implications. Cell Death Differ (2007) 3.19
Mechanisms of cytochrome c release from mitochondria. Cell Death Differ (2006) 3.13
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet (1994) 3.05
Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol (2001) 3.05
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet (1996) 2.93
Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. Oncogene (2007) 2.85
Two distinct pathways leading to nuclear apoptosis. J Exp Med (2000) 2.84
Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ (2008) 2.84
The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. J Exp Med (1997) 2.83
Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med (1998) 2.80
Mitochondrial release of caspase-2 and -9 during the apoptotic process. J Exp Med (1999) 2.79
Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene (2009) 2.74
DNA copy number losses in human neoplasms. Am J Pathol (1999) 2.73
Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death Dis (2010) 2.69
Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J (2000) 2.65
The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med (2000) 2.62
The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol (1998) 2.60
Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ (2007) 2.58
Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun (2001) 2.56
The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2-related proteins. J Exp Med (1998) 2.51
The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol (1999) 2.40
Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med (1996) 2.39
Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J Cell Biol (1997) 2.35
Apoptosis in yeast: triggers, pathways, subroutines. Cell Death Differ (2010) 2.34
The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. Cell Death Differ (2009) 2.29
A peripheral blood diagnostic test for acute rejection in renal transplantation. Am J Transplant (2012) 2.25
NADH oxidase activity of mitochondrial apoptosis-inducing factor. J Biol Chem (2001) 2.22
Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma. Eur Respir J (2007) 2.16
Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene (2010) 2.15
Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J Exp Med (2001) 2.07
The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ (2008) 2.01
Inter-neonatal intensive care unit variation in discharge timing: influence of apnea and feeding management. Pediatrics (2001) 1.98
Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta (1998) 1.97
Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst (2000) 1.95
Molecular characteristics of immunogenic cancer cell death. Cell Death Differ (2007) 1.92
Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia. Oncogene (2011) 1.87
Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. Cell Death Differ (1999) 1.84
Quantitative brain magnetic resonance imaging in girls with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry (2001) 1.84
Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene (2006) 1.83
Mitochondrial dysfunctions in circulating T lymphocytes from human immunodeficiency virus-1 carriers. Blood (1995) 1.83
Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett (2000) 1.82
Apoptosis. Mitochondria--the death signal integrators. Science (2000) 1.81
No death without life: vital functions of apoptotic effectors. Cell Death Differ (2008) 1.80
Apoptosis-inducing factor is a major contributor to neuronal loss induced by neonatal cerebral hypoxia-ischemia. Cell Death Differ (2006) 1.77
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene (2010) 1.75
Metacaspases are caspases. Doubt no more. Cell Death Differ (2010) 1.74
Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ (2002) 1.72
Experimental Borrelia burgdorferi infection in inbred mouse strains: antibody response and association of H-2 genes with resistance and susceptibility to development of arthritis. Eur J Immunol (1991) 1.71
GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization. Oncogene (2006) 1.65
Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ (2002) 1.64
Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. J Immunol (1996) 1.64
Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ (2013) 1.64
Dominant cell death induction by extramitochondrially targeted apoptosis-inducing factor. FASEB J (2001) 1.64
Genomic DNA pooling for whole-genome association scans in complex disease: empirical demonstration of efficacy in rheumatoid arthritis. Genes Immun (2006) 1.64
Apoptosis-inducing factor (AIF): caspase-independent after all. Cell Death Differ (2004) 1.64
Bcl-2 down-regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells. Cell Death Differ (2000) 1.64
Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women's HIV Study Group. CMAJ (1999) 1.63
Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells. Cell Death Differ (2009) 1.62
In vitro- and ex vivo-derived cytolytic leukocytes from granzyme A x B double knockout mice are defective in granule-mediated apoptosis but not lysis of target cells. J Exp Med (1997) 1.61
Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene (2000) 1.61
Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene (2008) 1.60
Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets (2010) 1.60
Apoptosis control in syncytia induced by the HIV type 1-envelope glycoprotein complex: role of mitochondria and caspases. J Exp Med (2000) 1.59
Role of TCR zeta chain in T cell development and selection. Science (1994) 1.59
Autophagy in aging, disease and death: the true identity of a cell death impostor. Cell Death Differ (2009) 1.58
Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet (2001) 1.58
Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett (1996) 1.58
Illicit survival of cancer cells during polyploidization and depolyploidization. Cell Death Differ (2010) 1.57
Taurocholate transport by rat liver sinusoidal membrane vesicles: evidence of sodium cotransport. Hepatology (1982) 1.57